1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Mental health, behavioural and neurodevelopmental conditions
  5. Psychosis and schizophrenia

Schizophrenia: omega-3 fatty acid medicines

Evidence summary [ESUOM19] Published: 24 September 2013

  • Advice
  • Information for the public
  • Key points from the evidence
  • Overview for healthcare professionals
  • Relevance to NICE guidance programmes
  • Intervention and alternatives
  • Evidence review: efficacy
  • Evidence review: safety
  • Evidence review: economic issues
  • Evidence strengths and limitations
  • Summary for patients
  • References
  • Development of this evidence summary
  • Appendix: Search strategy and evidence selection
  • About 'Evidence summaries: unlicensed or off-label medicines'
Download (PDF)

Advice

  • Next

Summary for patients

Summary for patients

A summary written for patients is available on the NICE website.


  • Next